keyword
MENU ▼
Read by QxMD icon Read
search

Silodosin

keyword
https://www.readbyqxmd.com/read/28255867/benign-prostatic-obstruction-relief-in-patients-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-enlargement-undergoing-endoscopic-surgical-procedures-or-therapy-with-alpha-blockers-a-review-of-urodynamic-studies
#1
REVIEW
Ferdinando Fusco, Massimiliano Creta, Vittorio Imperatore, Nicola Longo, Ciro Imbimbo, Herbert Lepor, Vincenzo Mirone
Benign prostatic obstruction (BPO) contributes to the genesis of lower urinary tract symptoms as well as to pathologic remodeling of the lower and upper urinary tract in patients with benign prostate enlargement. Urodynamic studies demonstrate that both medical therapy with alpha-blockers (ABs) and endoscopic surgical procedures provide BPO relief. However, the magnitude of improvement is higher after surgery. Among ABs, silodosin is associated with the highest improvement of bladder outlet obstruction index (BOOI)...
March 2, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28116737/efficacy-of-silodosin-dose-in-medical-expulsive-therapy-for-distal-ureteral-stones-a-retrospective-study
#2
Cem Nedim Yuceturk, Mumtaz Dadali, Muhammed Sahin Bagbanci, Berat Cem Ozgur, Yasin Aydogmus, Yildiray Yildiz, Muhammet Fatih Kilinc
PURPOSE: We aimed to investigate the efficacy of silodosin 4 mg/day and 8 mg/day for medical expulsive therapy(MET) of lower ureteral stones. MATERIALS AND METHODS: We retrospectively analyzed the medical records of 161 patients admitted to urologyclinics of Ahi Evran University Medical Faculty and Ankara Training and Research Hospital with distal ureteralstones and treated with MET with different doses of silodosin between January 2013 and August 2015. 81 patientswere treated with silodosin 4mg/day in group-1 and 80 patients with silodosin 8mg/day in group-2...
January 18, 2017: Urology Journal
https://www.readbyqxmd.com/read/28063187/characterization-of-degradation-products-of-silodosin-under-stress-conditions-by-liquid-chromatography-fourier-transform-mass-spectrometry
#3
Sukanya Pandeti, Tadigoppula Narender, Sripadi Prabhakar, Thota Jagadeswar Reddy
RATIONALE: Silodosin (SDN) is a novel α1 -adrenoceptor antagonist in the treatment of benign prostatic hyperplasia (BPH). The presence of degradation products in a drug affects not only the quality, but also the safety and efficacy of drug formulation. Thus, it is essential to develop an efficient analytical method which could be useful to selectively separate, identify and characterise of all possible degradation products of SDN which is mandatory in drug development processes. METHODS: SDN was subjected to forced degradation under hydrolytic (acid, base and neutral), oxidative, photolytic and thermal stress conditions...
March 30, 2017: Rapid Communications in Mass Spectrometry: RCM
https://www.readbyqxmd.com/read/28042309/the-link-between-vascular-dysfunction-bladder-ischemia-and-aging-bladder-dysfunction
#4
REVIEW
Karl-Erik Andersson, Donna B Boedtkjer, Axel Forman
The vascular supply to the human bladder is derived mainly from the superior and inferior vesical arteries, the latter being directly connected to the internal iliac artery. Aging is associated with an impairment of blood vessel function and changes may occur in the vasculature at the molecular, cellular and functional level. Pelvic arterial insufficiency may play an important role in the development of bladder dysfunctions such as detrusor overactivity (DO) and the overactive bladder syndrome. Chronic ischemia-related bladder dysfunction may progress to bladder underactivity and it would be desirable to treat not only lower urinary tract symptoms (LUTS) induced by chronic ischemia, but also the progression of the morphological bladder changes...
January 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27889014/-the-role-of-alpha-blockers-in-the-treatment-of-lower-urinary-tract-symptoms-benign-prostatic-hyperplasia-are-all-the-same-silodosin-in-real-life
#5
A Alcántara Montero
The lower urinary tract symptoms (LUTS) are very common in men, particularly in people over 65 years. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in males, and is a common cause of impaired quality of life. Alpha blockers monotherapy represent the treatment of choice in patients with moderate-severe LUTS secondary to BPH. Silodosin is currently the most α1A uroselective alpha blocker, uroselectivity which has been confirmed in several studies both in vitro and in vivo. In this paper the main benefits of silodosin are analyzed in both phase III clinical trials (standard approach) as in "real life" (analyzing the study SiRE [Silodosin in Real-life Evaluation], phase IV study), to validate the test data recording and confirm the positive benefit-risk profile of silodosin in a context that can reflect more closely the clinical practice...
July 2016: Semergen
https://www.readbyqxmd.com/read/27866053/lc-esi-ms-ms-evaluation-of-forced-degradation-behaviour-of-silodosin-in-vitro-anti-cancer-activity-evaluation-of-silodosin-and-major-degradation-products
#6
Chiguru Vishnuvardhan, Baikadi Saibaba, Lingesh Allakonda, Debasish Swain, S Gananadhamu, R Srinivas, N Satheeshkumar
Silodosin (SLD) a novel α1-adrenoceptor antagonist was subjected to forced degradation involving hydrolysis (acidic, alkaline and neutral), oxidative, photolysis and thermal stress, as per ICH specified conditions. The drug underwent significant degradation under hydrolytic (acidic, alkaline and neutral) and oxidative stress conditions whereas, it was found to be stable under other stress conditions. A rapid, precise, accurate and robust chromatographic method for the separation of the drug and its degradation products (DPs) was developed on a Fortis C18 analytical column (150×4...
February 5, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/27864702/selective-spectrofluorimetric-method-with-enhanced-sensitivity-for-determination-of-silodosine-in-dosage-form-and-human-plasma-application-to-stability-studies-and-content-uniformity-testing
#7
Mahmoud A Omar, Abdel-Maaboud I Mohamed, Sayed M Derayea, Mohamed A Hammad, Abobakr A Mohamed
A novel, sensitive and selective spectrofluorimetric method has been developed and validated for determination of silodosine (SLD) in its dosage form and human plasma. The method is based on nucleophilic substitution reaction of SLD with 5-(dimethylamino) naphthalene-1-sulfonyl chloride (dansyl chloride) in presence of 5.0 × 10(-4) M sodium carbonate (pH 10.50) to yield a highly fluorescent derivative that was measured at 435 nm after excitation at 347 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized...
November 19, 2016: Journal of Fluorescence
https://www.readbyqxmd.com/read/27864032/%C3%AE-1a-adrenergic-receptor-antagonism-improves-erectile-and-cavernosal-responses-in-rats-with-cavernous-nerve-injury-and-enhances-neurogenic-responses-in-human-corpus-cavernosum-from-patients-with%C3%A2-erectile-dysfunction-secondary-to-radical-prostatectomy
#8
Juan I Martínez-Salamanca, José M La Fuente, Eduardo Martínez-Salamanca, Argentina Fernández, Augusto J Pepe-Cardoso, Nuno Louro, Joaquín Carballido, Javier Angulo
INTRODUCTION: Cavernous nerve injury (CNI) in rats and radical prostatectomy (RP) in men result in loss of nitrergic function and increased adrenergic-neurogenic contractions of cavernosal tissue. AIM: To evaluate the modulation of the α-adrenergic system as a strategy to relieve erectile dysfunction (ED) and functional cavernosal alterations induced by CNI. METHODS: A non-selective α-blocker (phentolamine 1 mg/kg daily), a selective α1A-blocker (silodosin [SILOD] 0...
December 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27845695/-prognostic-factors-for-the-efficacy-of-silodosin-in-the-treatment-of-symptomatic-benign-prostatic-hyperplasia-subanalysis-of-the-ural-study
#9
MULTICENTER STUDY
Jesús Salinas-Casado, Miguel Vírseda-Chamorro, Santiago Méndez-Rubio, Marcos Luján-Galán, Manuel Esteban-Fuertes, Jesús Moreno-Sierra
OBJECTIVE: To identify the prognostic factors influencing the clinical and urodynamics results on symptomatic benign prostatic hypertrophy (BHP) treatment in a series of patients with silodosin therapy from the URAL study. METHODS: A retrospective study was performed in a cohort of 318 patients with BPH which underwent silodosine treatment, during at least 12 weeks. RESULTS: Univariate analysis demonstrated that the variables in relationship with a decrease of urinary symptoms` punctuation postreatment (measured with the IPSS Questionnaire), a maximum peak flow (Q max) postreatment equal or superior to 15 ml/s, a postreatment postvoid residual lower to 100 ml, and a postreatment obstruction index ( Bladder Outlet Obstruction Index: BOOI) equal or lower to 20 cm H2O, presented such both as a clinical and urodynamic character...
November 2016: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/27752927/%C3%AE-1-blockers-in-men-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-obstruction-is-silodosin-different
#10
REVIEW
Claus G Roehrborn, Francisco Cruz, Ferdinando Fusco
Available α1-blockers (ABs) have different profiles of receptor selectivity. Silodosin exhibits the highest selectivity for the α1A adrenergic receptor. This pharmacological feature couples with a singular urodynamic and clinical profile. The magnitude of bladder outlet obstruction improvement in patients receiving silodosin is higher if compared to other ABs. From a clinical point of view, current evidence suggests an advantage in favor of silodosin in terms of nocturia improvement and cardiovascular safety...
January 2017: Advances in Therapy
https://www.readbyqxmd.com/read/27747994/in-vivo-metabolic-investigation-of-silodosin-using-uhplc-qtof-ms-ms-and-in-silico-toxicological-screening-of-its-metabolites
#11
Chiguru Vishnuvardhan, Saibaba Baikadi, Roshan M Borkar, R Srinivas, N Satheeshkumar
Silodosin (SLD) is a novel α1-adrenoceptor antagonist which has shown promising clinical efficacy and safety in patients with benign prostatic hyperplasia (BPH). However, lack of information about metabolism of SLD prompted us to investigate metabolic fate of SLD in rats. To identify in vivo metabolites of SLD, urine, feces and plasma were collected from Sprague-Dawley rats after its oral administration. The samples were prepared using an optimized sample preparation approach involving protein precipitation followed by solid-phase extraction and then subjected to LC/HR-MS/MS analysis...
October 2016: Journal of Mass Spectrometry: JMS
https://www.readbyqxmd.com/read/27747715/coma-after-quetiapine-fumarate-intentional-overdose-in-a-71-year-old-man-a-case-report
#12
S Gibiino, A Trappoli, B Balzarro, A R Atti, D De Ronchi
A 71-year-old man developed coma with severe respiratory failure, hypotension, and tachycardia induced by the intentional ingestion of quetiapine fumarate extended release (XR) 20 g. At the time, he had been treated for bipolar depression with venlafaxine 75 mg/day, lamotrigine 100 mg/day, pregabalin 75 mg/day, and quetiapine XR 400 mg/day for approximately 1 year. Comorbidities were hypertension treated with metoprolol, diabetes mellitus type 2 treated with metformin, and benign prostatic hyperplasia treated with silodosin...
December 2015: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27747713/a-suspected-case-of-silodosin-induced-erythroderma
#13
Annie Liu, Lyne Giroux
An 86-year-old man developed a suspected severe erythroderma during treatment with silodosin (dosage unknown) for benign prostatic enlargement. Two weeks after starting silodosin, he developed a total-body scaling dermatitis. A biopsy was planned but the patient improved at his subsequent visit and it was not taken. Silodosin was discontinued and the patient received UVB phototherapy, clobetasol ointment, and several bland and protective skin-care measures. One week after the initial presentation, the patient demonstrated improvement in his total-body scaling...
December 2015: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27729995/effectiveness-of-on-demand-silodosin-in-the-treatment-of-premature-ejaculation-in-patients-dissatisfied-with-dapoxetine-a-randomized-control-study
#14
Gajanan S Bhat, Anuradha Shastry
INTRODUCTION: Premature ejaculation is a common sexual disorder, which is usually underreported. Multiple treatment methodologies are in use due to the absence of an effective, universally acceptable treatment modality. The most common drug used is dapoxetine, which has adverse effects limiting its long-term use. Hence, we decided to evaluate the effectiveness of 'on demand' silidosin 4 mg in patients with premature ejaculation, who were dissatisfied with dapoxetine 30 mg. MATERIAL AND METHODS: The study included 64 patients who reported premature ejaculation who were unhappy with the treatment with 'on demand' dapoxetine 30 mg, either due to its adverse effects or because of its overall inefficacy...
2016: Central European Journal of Urology
https://www.readbyqxmd.com/read/27727093/-lower-urinary-tract-symptoms-and-pelvic-floor-dysfunction-in-renal-transplant-candidates-and-recipients
#15
R Thuret, S Hurel, F Kleinclauss, M O Timsit
OBJECTIVES: To describe lower urinary tract symptoms (LUTS) and their management in renal transplant candidates and recipients. MATERIAL AND METHODS: Relevant publications were identified through Medline (http://www.ncbi.nlm.nih.gov) and Embase (http://www.embase.com) database using the following keywords, alone or in association: "transplantation", "prostate hyperplasia", "transurethral resection of prostate", "urinary incontinence", "LUTS", "pelvic floor dysfunction"...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27709945/design-synthesis-and-biological-evaluation-of-novel-tetrahydroprotoberberine-derivatives-thpbs-as-selective-%C3%AE-1a-adrenoceptor-antagonists
#16
Diliang Guo, Jing Li, Henry Lin, Yu Zhou, Ying Chen, Fei Zhao, Haifeng Sun, Dan Zhang, Honglin Li, Brian K Shoichet, Lei Shan, Weidong Zhang, Xin Xie, Hualiang Jiang, Hong Liu
A novel series of tetrahydroprotoberberine derivatives (THPBs) were designed, synthesized, and evaluated as selective α1A-adrenergic receptors (AR) antagonists for the treatment of benign prostatic hyperplasia. On the basis of the pharmacophore model of the marketed drug silodosin, THPBs were modified by introducing an indole segment into their core scaffolds. In calcium assays, 7 out of 32 compounds displayed excellent antagonistic activities against α1A-ARs, with IC50 less than 250 nM. Among them, compound (S)-27 had the most potent biological activity; its IC50 toward α1A-AR was 12...
October 27, 2016: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/27687860/the-role-of-silodosin-as-a-new-medical-expulsive-therapy-for-ureteral-stones-a-meta-analysis
#17
Hui Ding, Zhongyun Ning, Yu Dai, Panfeng Shang, Li Yang
To evaluate the efficacy of Silodosin as a medical expulsive therapy of ureteral stones, we searched PubMed, EMBASE, the Cochrane Library, and CBM up to June 2015. All randomized controlled trials (RCTs) were identified in which patients were randomized to receive Silodosin versus placebo or other therapies for ureteral stones. Outcome measures assessed were overall stone expulsion rate (primary) and expulsion time, analgesics times, and the incidence of additional treatment and regarding treatment complications (secondary)...
October 2016: Renal Failure
https://www.readbyqxmd.com/read/27683251/intraprostatic-reflux-of-urine-induces-inflammation-in-a-rat
#18
Yasuhito Funahashi, Tsuyoshi Majima, Yoshihisa Matsukawa, Tokunori Yamamoto, Masaki Yoshida, Momokazu Gotoh
BACKGROUND: We examined whether urine reflux into the prostate can induce prostatic inflammation in a rat and evaluated the effect of α1-adrenoreceptor antagonist. METHODS: Experiment 1: Male Sprague-Dawley rats were injected with 500 µl of Evans Blue through the urethral orifice. Intravesical pressure was measured, and the prostate was excised to evaluate urine reflux. Experiment 2: Rats were injected with 500 µl urine or saline (control) from the urethral orifice...
February 2017: Prostate
https://www.readbyqxmd.com/read/27629059/new-medical-treatments-for-lower-urinary-tract-symptoms-due-to-benign-prostatic-hyperplasia-and-future-perspectives
#19
REVIEW
Simone Albisinni, Ibrahim Biaou, Quentin Marcelis, Fouad Aoun, Cosimo De Nunzio, Thierry Roumeguère
BACKGROUND: Lower Urinary Tract Symptoms (LUTS) in men are a common clinical problem in urology and have been historically strictly linked to benign prostatic hyperplasia (BPH), which may lead to bladder outlet obstruction (BOO). New molecules have been approved and have entered the urologists' armamentarium, targeting new signaling pathways and tackling specific aspects of LUTS. Objective of this review is to summarize the evidence regarding the new medical therapies currently available for male non-neurogenic LUTS, including superselective α1-antagonists, PDE-5 inhibitors, anticholinergic drugs and intraprostatic onabotulinum toxin injections...
September 15, 2016: BMC Urology
https://www.readbyqxmd.com/read/27615436/comparison-of-silodosin-and-naftopidil-for-efficacy-in-the-treatment-of-benign-prostatic-enlargement-complicated-by-overactive-bladder-a-randomized-prospective-study-sniper-study
#20
Yoshihisa Matsukawa, Yasuhito Funahashi, Shun Takai, Tsuyoshi Majima, Tadashi Ogawa, Harunori Narita, Masashi Kato, Momokazu Gotoh
PURPOSE: We investigated the efficacy of 2 α1-blockers with different affinities for the α1-adrenoceptor subtypes silodosin and naftopidil in the treatment of benign prostatic enlargement complicated by overactive bladder. MATERIALS AND METHODS: This was a prospective, open label, randomized, multicenter study of 350 outpatients with untreated benign prostatic enlargement associated with urinary urgency at least once per week and an OABSS (Overactive Bladder Symptom Score) of 3 or greater...
September 8, 2016: Journal of Urology
keyword
keyword
105114
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"